新华制药公告，公司于2024年12月9日与NovoSana（Europe）B.V.签订的《股权收购意向协议》基于双 方未达成一致意见，根据协议终止条款，意向协议终止，所涉及的所有条款均终止履行。意向协议终止 不会对公司生产经营和财务状况产生不利影响，不存在损害公司和全体股东利益的情形。 ...

终止《股权收购意向协议》系本公司审慎研究后作出的决定，不会影响本公司现有生产经营活动，也不 会对本公司的发展造成不利影响，不存在损害本公司及全体股东，特别是中小股东利益的情形。 山东新华制药（000756）股份(00719)发布公告，有关本公司与挪亚圣诺(欧洲)公司签署《股权收购意向 协议》。股权收购意向协议仅系各方经友好协商达成的初步意向，然而，经进一步讨论及磋商后，订约 方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议，该项目亦不会进 行。故此，本公司已决定终止该等股权收购意向协议。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，有关本公司与挪亚圣诺(欧洲)公司签署《股权收 购意向协议》。股权收购意向协议仅系各方经友好协商达成的初步意向，然而，经进一步讨论及磋商 后，订约方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议，该项目亦 不会进行。故此，本公司已决定终止该等股权收购意向协议。 终止《股权收购意向协议》系本公司审慎研究后作出的决定，不会影响本公司现有生产经营活动，也不 会对本公司的发展造成不利影响，不存在损害本公司及全体股东，特别是中小股东利益的情形。 ...

Group 1 - The Nipah virus outbreak in India has raised concerns, particularly in West Bengal, but its impact on China is considered minimal as no cases have been reported in the country [1] - The market has shown increased interest in stocks related to virus prevention and diagnostics, with companies like Capbio and Da'an Gene experiencing significant stock price increases [1] - The Nipah virus has a transmission period of 3 to 14 days, with initial symptoms resembling influenza, making early detection crucial for effective intervention [1] Group 2 - Several A-share listed companies have announced their developments in Nipah virus detection technologies, including Wanfu Bio and Shengxiang Bio, which have launched various testing kits [3][5] - Capbio has developed a Nipah virus nucleic acid detection kit, providing essential support for global quarantine and disease control monitoring [5] - Some companies, such as Hualan Vaccine and Yirui Bio, have clarified that they do not have any products related to Nipah virus prevention or treatment [5][6]

Core Viewpoint - Xinhua Pharmaceutical (000756) clarified on January 27 that it has not received any information regarding the urgent shortage of ibuprofen in India, despite the drug's common use for antipyretic, analgesic, and anti-inflammatory purposes [1]. Company Summary - Xinhua Pharmaceutical stated that ibuprofen is primarily used for reducing fever, relieving pain, and providing anti-inflammatory effects, and it is a commonly used non-steroidal anti-inflammatory drug [1].

证券之星消息，1月26日化学制药板块较上一交易日下跌0.18%，富祥药业领跌。当日上证指数报收于 4132.61，下跌0.09%。深证成指报收于14316.64，下跌0.85%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入11.16亿元，游资资金净流入2.2亿元，散户资金净 流出13.37亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600789 | 鲁抗医药 | 26653 | 29.72% | -1.98亿 | -14.72% | -2.01 乙 | -14.99% | | 300723 | 一品红 | 1.00 Z | 13.23% | 2678.72万 | 3.54% | -1.27 Z | -16.76% ...

Core Viewpoint - The current market is experiencing a shift from value investing to speculative trading, with significant pressure from major players on core assets, leading to a fragmented market environment [1][3]. Market Analysis - Major players are holding high-quality core assets but have been suppressing their value, which has led to a questioning of the established value investment framework [3]. - The market is showing signs of recovery, particularly in sectors like commercial aerospace and artificial intelligence, despite the ongoing pressure from major players [1][5]. - The current market conditions resemble the volatility seen in late 2015, with a potential for significant price movements as new capital enters at lower levels [1][3]. Trading Signals - There are indications of a structural market recovery, with a notable increase in the number of stocks hitting daily price limits, particularly in the aerospace sector [5][6]. - The data suggests that the market is currently in a phase similar to the volatility observed in November-December, with a potential for a broader recovery if major players do not continue aggressive selling [3][8]. Sector Performance - The aerospace sector has shown a strong resurgence, with 22 stocks hitting their daily limit, indicating renewed investor interest [5][6]. - Other sectors such as robotics and advanced packaging are also gaining traction, suggesting a shift towards growth-oriented investments [5][6]. Investor Behavior - Retail investors are showing signs of reducing their positions, while institutional investors are also pulling back, reflecting a cautious approach amidst market volatility [3][8]. - The market is characterized by a split between speculative trading and traditional value investing, with investors advised to avoid core assets under current conditions [8].

山东新华制药股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开了薪酬与考 核委员会 2025 年第二次会议、第十一届董事会 2025 年第二次临时会议，审议通过了《关于 调整 2021 年 A 股股票期权激励计划首次授予行权价格、激励对象名单及授予期权数量并注销 部分期权的议案》及《关于调整 2021 年 A 股股票期权激励计划预留授予行权价格并注销部分 期权的议案》。 由于公司 2021 年 A 股股票期权激励计划首次授予激励对象中岗位调整 1 人，解除合同 2 人，退休 4 人，根据公司《2021 年 A 股股票期权激励计划（草案）》的规定，上述人员已不 具备激励对象资格，公司对其已获授但未行权的 46.20 万份股票期权予以注销，具体内容详 见公司于 2026 年 1 月 5 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于调整 2021 年 A 股股票期权激励计划首次授予行权价格、激励对象名单及授予期权数量并注销部分期权的公 告》（公告编号：2025-74）；由于公司 2021 年股票期权激励计划预留授予第一个行权期已 于 2025 年 12 月 26 日届满，3 ...

山东新华制药（000756）股份(00719)发布公告，公司本次注销7名首次授予激励对象已获授但未行权的 股票期权共计46.20万份，占注销前公司总股本的0.07%;公司本次注销35名预留授予激励对象已获授但 未行权的股票期权共计59.50万份，占注销前公司总股本的0.09%。公司已在中国证券登记结算有限责任 公司深圳分公司办理完成上述46.20万份及59.50万份已获授的股票期权注销事宜。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，公司本次注销7名首次授予激励对象已获授但未 行权的股票期权共计46.20万份，占注销前公司总股本的0.07%;公司本次注销35名预留授予激励对象已 获授但未行权的股票期权共计59.50万份，占注销前公司总股本的0.09%。公司已在中国证券登记结算有 限责任公司深圳分公司办理完成上述46.20万份及59.50万份已获授的股票期权注销事宜。 ...